Prelude Capital Management’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-3,694
| Closed | -$251K | – | 2431 |
|
|
2019
Q3 | $251K | Buy |
+3,694
| New | +$254K | 0.01% | 703 |
|
|
2019
Q2 | – | Sell |
-315
| Closed | -$22K | – | 2350 |
|
|
2019
Q1 | $22K | Sell |
315
-28
| -8% | -$2.08K | ﹤0.01% | 1302 |
|
|
2018
Q4 | $22K | Buy |
343
+23
| +7% | +$1.61K | ﹤0.01% | 1230 |
|
|
2018
Q3 | $22K | Buy |
320
+120
| +60% | +$7.02K | ﹤0.01% | 1297 |
|
|
2018
Q2 | $10K | Hold |
200
| – | – | ﹤0.01% | 1493 |
|
|
2018
Q1 | $6K | Buy |
+200
| New | +$6.64K | ﹤0.01% | 1411 |
|
|
2017
Q4 | – | Sell |
-1,200
| Closed | -$39K | – | 1883 |
|
|
2017
Q3 | $39K | Buy |
+1,200
| New | +$37.8K | ﹤0.01% | 1169 |
|
|
2017
Q1 | – | Sell |
-5,300
| Closed | -$156K | – | 1909 |
|
|
2016
Q4 | $156K | Buy |
5,300
+3,794
| +252% | +$116K | 0.02% | 671 |
|
|
2016
Q3 | $44K | Sell |
1,506
-1,900
| -56% | -$52.9K | ﹤0.01% | 1085 |
|
|
2016
Q2 | $88K | Buy |
3,406
+1,106
| +48% | +$29.4K | 0.01% | 813 |
|
|
2016
Q1 | $57K | Buy |
+2,300
| New | +$63.1K | 0.01% | 944 |
|
|
2015
Q1 | – | Sell |
-2,200
| Closed | -$70K | – | 2311 |
|
|
2014
Q4 | $70K | Sell |
2,200
-300
| -12% | -$9.76K | 0.01% | 1144 |
|
|
2014
Q3 | $71K | Buy |
2,500
+300
| +14% | +$8.36K | 0.01% | 1251 |
|
|
2014
Q2 | $60K | Hold |
2,200
| – | – | 0.01% | 1301 |
|
|
2014
Q1 | $58K | Buy |
+2,200
| New | +$63.1K | 0.01% | 1248 |
|
Prelude Capital Management's GHDX Position: Q4 2019 in Review
Prelude Capital Management sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 3,694 shares — an estimated $251K sold.
Prelude Capital Management first reported a position in GHDX in Q1 2014 and held it in 15 quarters. The position peaked at $251K in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Prelude Capital Management reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Prelude Capital Management sold 3,694 Genomic Health, Inc. shares in Q4 2019, an estimated $251K.
- Prelude Capital Management first reported a position in Genomic Health, Inc. in Q1 2014 and held it in 15 quarters.
- Prelude Capital Management's Genomic Health, Inc. position peaked at $251K in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.